Agilent Technologies Inc. (NYSE: A) introduced the 1260 Infinity Multi-Detector Bio-SEC Solution, the latest innovation in its complete line of Infinity liquid chromatography systems. This new size-exclusion chromatography (SEC) system features advanced light-scattering detection capabilities, fully bio-inert instrumentation, high-resolution columns and intuitive software. These features take SEC—the gold standard in protein aggregate analysis—to a whole new level of speed, sensitivity and reproducibility.
“The development of large-molecule protein biotherapeutics is expected to yield blockbuster effects on human clinical outcomes, but in order to achieve that success, the biopharmaceutical industry requires equally vigorous research, measurement and analysis technology to fully ensure the safety and efficacy of those compounds,” said Helmut Schulenberg-Schell, director of business development for Agilent’s Liquid Phase Separation Division. “Our powerful new SEC LC solution provides biopharmaceutical researchers with previously unattainable robust measurement capabilities with unmatched reproducibility.”
SEC is used for protein sizing and studying aggregates and bio-conjugates. Even at the lowest concentrations, these “mis-folded” proteins that accumulate together in recombinant protein and monoclonal antibody biologics can be toxic and cause disease-producing effects. They must be identified and remediated at every phase of the drug development lifecycle—from early research, to clinical formulation, to large-scale manufacturing.
Agilent’s fully bio-inert 1260 Infinity Multi-Detector Bio-SEC Solution provides maximum sensitivity and accuracy through advanced detection capabilities and sophisticated yet intuitive software capabilities. Used throughout the drug development lifecycle, this technology can significantly simplify and speed up workflow, reducing the valuable time and expense associated with bringing biopharmaceuticals to market.